WO2019109067A3 - Promédicaments à base de créatine, compositions et procédés d'utilisation associés - Google Patents
Promédicaments à base de créatine, compositions et procédés d'utilisation associés Download PDFInfo
- Publication number
- WO2019109067A3 WO2019109067A3 PCT/US2018/063580 US2018063580W WO2019109067A3 WO 2019109067 A3 WO2019109067 A3 WO 2019109067A3 US 2018063580 W US2018063580 W US 2018063580W WO 2019109067 A3 WO2019109067 A3 WO 2019109067A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- creatine
- creatine prodrugs
- prodrugs
- Prior art date
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title abstract 6
- 229960003624 creatine Drugs 0.000 title abstract 3
- 239000006046 creatine Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018375199A AU2018375199B2 (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
EP18883842.9A EP3717453A4 (fr) | 2017-12-01 | 2018-12-03 | Promédicaments à base de créatine, compositions et procédés d'utilisation associés |
KR1020207018932A KR102678696B1 (ko) | 2017-12-01 | 2018-12-03 | 크레아틴 전구약물, 조성물과 이의 사용 방법 |
CN201880077165.5A CN111417620B (zh) | 2017-12-01 | 2018-12-03 | 肌酸前药、其组合物以及使用方法 |
BR112020010805-7A BR112020010805B1 (pt) | 2017-12-01 | 2018-12-03 | Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição farmacêutica |
US16/764,969 US11332438B2 (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
SG11202004336VA SG11202004336VA (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
JP2020527818A JP7433226B2 (ja) | 2017-12-01 | 2018-12-03 | クレアチンプロドラッグ、組成物及びその使用方法 |
MX2020005707A MX2020005707A (es) | 2017-12-01 | 2018-12-03 | Profarmacos de creatina, composiciones y metodos de uso de estos. |
CA3082184A CA3082184A1 (fr) | 2017-12-01 | 2018-12-03 | Promedicaments a base de creatine, compositions et procedes d'utilisation associes |
IL274701A IL274701B2 (en) | 2017-12-01 | 2020-05-15 | Promote drugs, compositions and methods of their use |
CONC2020/0006542A CO2020006542A2 (es) | 2017-12-01 | 2020-05-28 | Profármacos de creatina, composiciones y métodos de uso de estos |
US17/706,283 US11753369B2 (en) | 2017-12-01 | 2022-03-28 | Creatine prodrugs, compositions and methods of use thereof |
US18/352,959 US20240092731A1 (en) | 2017-12-01 | 2023-07-14 | Creatine prodrugs, compositions and methods of use thereof |
JP2023152930A JP2024009811A (ja) | 2017-12-01 | 2023-09-20 | クレアチンプロドラッグ、組成物及びその使用方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593731P | 2017-12-01 | 2017-12-01 | |
US62/593,731 | 2017-12-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/764,969 A-371-Of-International US11332438B2 (en) | 2017-12-01 | 2018-12-03 | Creatine prodrugs, compositions and methods of use thereof |
US17/706,283 Division US11753369B2 (en) | 2017-12-01 | 2022-03-28 | Creatine prodrugs, compositions and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019109067A2 WO2019109067A2 (fr) | 2019-06-06 |
WO2019109067A3 true WO2019109067A3 (fr) | 2020-03-26 |
Family
ID=66665277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/063580 WO2019109067A2 (fr) | 2017-12-01 | 2018-12-03 | Promédicaments à base de créatine, compositions et procédés d'utilisation associés |
Country Status (15)
Country | Link |
---|---|
US (3) | US11332438B2 (fr) |
EP (1) | EP3717453A4 (fr) |
JP (2) | JP7433226B2 (fr) |
KR (1) | KR102678696B1 (fr) |
CN (1) | CN111417620B (fr) |
AR (1) | AR118403A1 (fr) |
AU (1) | AU2018375199B2 (fr) |
BR (1) | BR112020010805B1 (fr) |
CA (1) | CA3082184A1 (fr) |
CO (1) | CO2020006542A2 (fr) |
IL (1) | IL274701B2 (fr) |
MX (1) | MX2020005707A (fr) |
SG (1) | SG11202004336VA (fr) |
TW (1) | TWI815832B (fr) |
WO (1) | WO2019109067A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3082184A1 (fr) | 2017-12-01 | 2019-06-06 | Ultragenyx Pharmaceutical Inc. | Promedicaments a base de creatine, compositions et procedes d'utilisation associes |
US11465486B1 (en) | 2021-08-13 | 2022-10-11 | Oshkosh Defense, Llc | Electrified military vehicle |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281996A1 (en) * | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine prodrugs, compositions and uses thereof |
US7319157B1 (en) * | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
US20150238453A1 (en) * | 2014-02-27 | 2015-08-27 | 4141 Holdings, Llc | Bio-available n-acetyl creatine species and compositions thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0718000B2 (ja) | 1985-05-15 | 1995-03-01 | 日本真空技術株式会社 | 合成樹脂被膜の形成方法 |
US4767627A (en) | 1985-05-29 | 1988-08-30 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
CA1340821C (fr) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Composes heterocycliques, ainsi que des adjuvants de produits anti-cancereux les comprenant |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
DK0595894T3 (da) | 1991-07-19 | 1996-05-13 | Uniroyal Chem Co Inc | Frøfilmsammensætninger |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
JPH0718000A (ja) * | 1993-06-18 | 1995-01-20 | Takeda Chem Ind Ltd | 新規ペプチド |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
EP1719510A1 (fr) | 1994-11-08 | 2006-11-08 | Avicenda Group, Inc. | Utilisation de la créatine ou d'analogues de la créatine pour le traitement de maladies du système nerveux |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
WO1997013507A1 (fr) | 1995-10-11 | 1997-04-17 | Avicena Group, Inc. | Utilisation d'analogues de creatine pour le traitement de troubles du metabolisme du glucose |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US6008252A (en) | 1996-07-26 | 1999-12-28 | Beale; Paxton K. | Method for increasing muscle mass in a mammal |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
WO1999007342A1 (fr) | 1997-08-11 | 1999-02-18 | Alza Corporation | Forme galenique d'un agent actif a liberation prolongee adaptee a la retention gastrique |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US20030008007A1 (en) | 2001-04-23 | 2003-01-09 | Jose Gutierrez-Rocca | Release pharmaceutical construct for gastric retention |
US20030013767A1 (en) | 2001-07-13 | 2003-01-16 | Samuel Bessman | Method of treating weight loss using creatine |
US20040219186A1 (en) | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
AU2002363998A1 (en) | 2001-12-15 | 2003-06-30 | Spherics, Inc. | Bioadhesive drug delivery system with enhanced gastric retention |
WO2003057197A1 (fr) | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Nouvelles formes posologiques pharmaceutiques et procede de production de ces formes posologiques |
DE10221344A1 (de) | 2002-05-14 | 2003-12-04 | Hannover Med Hochschule | Transgene Ratte und ihre Verwendung im Tiermodell für die humane Chorea Huntington Erkrankung sowie Nukleinsäurekonstrukte, Vektoren und Zellen zu ihrer Erzeugung |
KR101019778B1 (ko) * | 2002-05-16 | 2011-03-04 | 바이엘 크롭사이언스 게엠베하 | 피리딘 카복사마이드 유도체 및 이것의 살충제로서의 용도 |
CN1668645A (zh) | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
EP2567705A3 (fr) | 2002-06-04 | 2013-07-03 | Avicena Group, Inc. | Procédés de traitement de dysfonctionnements cognitifs par modulation du métabolisme énergétique du cerveau |
GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
US20060013876A1 (en) | 2002-06-26 | 2006-01-19 | Lohray Braj B | Novel floating dosage form |
US20040120983A1 (en) | 2002-12-23 | 2004-06-24 | Philip Connolly | Nutritional supplement |
WO2005108370A1 (fr) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | Composés du benzène |
CA2784420C (fr) | 2004-07-02 | 2020-11-10 | Baylor Research Institute | Methode de traitement d'une maladie de surcharge due a l'accumulation de glycogenes ou de polysaccharides |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
US20070012105A1 (en) | 2005-07-13 | 2007-01-18 | Barnes-Jewish Hospital | Method and apparatus for resistive characteristic assessment |
US20070032750A1 (en) | 2005-07-15 | 2007-02-08 | Jeffrey Oster | Muscle strength assessment system |
US7683043B2 (en) | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
WO2007146085A2 (fr) | 2006-06-06 | 2007-12-21 | Xenoport, Inc. | Promédicaments de phosphate de créatine, compositions et utilisations de ceux-ci |
AU2007332800A1 (en) | 2006-12-07 | 2008-06-19 | Avicena Group, Inc. | Creatine compositions for skin treatment |
WO2008101310A1 (fr) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Créatine-acides gras |
WO2008101309A1 (fr) | 2007-02-20 | 2008-08-28 | Multi Formulations Ltd. | Composés créatine-acides gras |
US8546369B2 (en) | 2008-05-30 | 2013-10-01 | Northern Innovations Holding Corp. | Salts of creatine imino sugar amides |
WO2010005692A2 (fr) | 2008-06-16 | 2010-01-14 | E. I. Du Pont De Nemours And Company | Carbonyl-amidines cycliques insecticides |
EP2269980A4 (fr) | 2008-12-24 | 2011-05-18 | Vertex Closed Joint Stock Company | Amides de créatine, procédé de production, et produit possédant une action neuroprotectrice |
CN102781438A (zh) | 2009-12-30 | 2012-11-14 | 贝勒研究院 | 用于阿尔茨海默病和脑衰老的补给疗法 |
JP2013528648A (ja) | 2010-06-14 | 2013-07-11 | ベイラー リサーチ インスティテュート | 成人ポリグルコサン小体病(apbd)を処置するためのトリヘプタノイン食 |
JP5702248B2 (ja) | 2011-07-28 | 2015-04-15 | 三菱製紙株式会社 | ナノファイバー、ナノファイバーの形成方法およびナノファイバー集合体の形成方法 |
CN103889993B (zh) | 2011-09-19 | 2017-05-31 | 吉奇亚公司 | 修饰的肌酸化合物 |
US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
DK2692719T3 (en) | 2012-07-30 | 2016-09-12 | Commissariat L Energie Atomique Et Aux Energies Alternatives | A process for the preparation of kreatinfedtestere, thus prepared and to their use kreatinfedtestere |
ITTO20121098A1 (it) | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
JP6689199B2 (ja) | 2013-08-30 | 2020-04-28 | モーメンティブ・パフォーマンス・マテリアルズ・インク | アミノ酸を含む湿気硬化性化合物 |
US20160289175A1 (en) | 2013-11-05 | 2016-10-06 | Ultragenyx Pharmaceutical Inc. | Creatine analogs and the use thereof |
ITTO20131070A1 (it) | 2013-12-24 | 2015-06-25 | Univ Degli Studi Genova | Applicazione terapeutica di un derivato di creatina |
CA2959387A1 (fr) | 2014-09-03 | 2016-03-10 | Lumos Pharma, Inc. | Synthese de cyclocreatine et des analogues de celle-ci |
US9617230B2 (en) | 2014-12-22 | 2017-04-11 | Farmington Pharma Development | Creatine prodrugs, compositions and methods of use thereof |
WO2016110822A1 (fr) | 2015-01-09 | 2016-07-14 | Universita' Degli Studi Di Genova | Dérivé de créatine biacyl carboxylique, utilisations et procédé de synthèse associés |
AR104144A1 (es) | 2015-03-30 | 2017-06-28 | Farmington Pharma Dev | Profármacos de análogos de fosfato de creatina, sus composiciones y sus usos |
CA3082184A1 (fr) | 2017-12-01 | 2019-06-06 | Ultragenyx Pharmaceutical Inc. | Promedicaments a base de creatine, compositions et procedes d'utilisation associes |
-
2018
- 2018-12-03 CA CA3082184A patent/CA3082184A1/fr active Pending
- 2018-12-03 MX MX2020005707A patent/MX2020005707A/es unknown
- 2018-12-03 SG SG11202004336VA patent/SG11202004336VA/en unknown
- 2018-12-03 CN CN201880077165.5A patent/CN111417620B/zh active Active
- 2018-12-03 BR BR112020010805-7A patent/BR112020010805B1/pt active IP Right Grant
- 2018-12-03 US US16/764,969 patent/US11332438B2/en active Active
- 2018-12-03 AR ARP180103527A patent/AR118403A1/es unknown
- 2018-12-03 JP JP2020527818A patent/JP7433226B2/ja active Active
- 2018-12-03 KR KR1020207018932A patent/KR102678696B1/ko active IP Right Grant
- 2018-12-03 EP EP18883842.9A patent/EP3717453A4/fr active Pending
- 2018-12-03 AU AU2018375199A patent/AU2018375199B2/en active Active
- 2018-12-03 WO PCT/US2018/063580 patent/WO2019109067A2/fr unknown
- 2018-12-03 TW TW107143208A patent/TWI815832B/zh active
-
2020
- 2020-05-15 IL IL274701A patent/IL274701B2/en unknown
- 2020-05-28 CO CONC2020/0006542A patent/CO2020006542A2/es unknown
-
2022
- 2022-03-28 US US17/706,283 patent/US11753369B2/en active Active
-
2023
- 2023-07-14 US US18/352,959 patent/US20240092731A1/en active Pending
- 2023-09-20 JP JP2023152930A patent/JP2024009811A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070281996A1 (en) * | 2006-06-06 | 2007-12-06 | Xenoport, Inc. | Creatine prodrugs, compositions and uses thereof |
US7319157B1 (en) * | 2007-02-20 | 2008-01-15 | Multi Formulations Ltd. | Creatine-fatty acids |
US20150238453A1 (en) * | 2014-02-27 | 2015-08-27 | 4141 Holdings, Llc | Bio-available n-acetyl creatine species and compositions thereof |
Non-Patent Citations (1)
Title |
---|
SAMAIN ET AL.: "Structure of scopafungin, a potent nonpolyene antifungal antibiotic", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 104, July 1982 (1982-07-01), pages 4129 - 4141, XP055694936 * |
Also Published As
Publication number | Publication date |
---|---|
US11753369B2 (en) | 2023-09-12 |
CN111417620A (zh) | 2020-07-14 |
AR118403A1 (es) | 2021-10-06 |
TWI815832B (zh) | 2023-09-21 |
BR112020010805A2 (pt) | 2020-11-10 |
IL274701A (en) | 2020-06-30 |
BR112020010805B1 (pt) | 2024-01-30 |
CO2020006542A2 (es) | 2020-06-09 |
AU2018375199B2 (en) | 2023-03-30 |
US11332438B2 (en) | 2022-05-17 |
JP2024009811A (ja) | 2024-01-23 |
US20220227703A1 (en) | 2022-07-21 |
CN111417620B (zh) | 2023-08-25 |
MX2020005707A (es) | 2020-08-20 |
TW201927368A (zh) | 2019-07-16 |
JP2021505537A (ja) | 2021-02-18 |
KR102678696B1 (ko) | 2024-06-27 |
JP7433226B2 (ja) | 2024-02-19 |
US20240092731A1 (en) | 2024-03-21 |
EP3717453A2 (fr) | 2020-10-07 |
CA3082184A1 (fr) | 2019-06-06 |
US20210002211A1 (en) | 2021-01-07 |
IL274701B1 (en) | 2024-03-01 |
EP3717453A4 (fr) | 2021-07-28 |
KR20200105833A (ko) | 2020-09-09 |
SG11202004336VA (en) | 2020-06-29 |
IL274701B2 (en) | 2024-07-01 |
WO2019109067A2 (fr) | 2019-06-06 |
AU2018375199A1 (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3848370A3 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
EP4327809A3 (fr) | Inhibiteurs de tyk2 et leurs utilisations | |
WO2016044556A3 (fr) | Inhibiteurs d'arginine méthyltransférase et leurs utilisations | |
WO2016130920A3 (fr) | Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation | |
WO2017106957A8 (fr) | Promédicaments liés à des lipides | |
WO2016149401A3 (fr) | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci | |
EP3675859A4 (fr) | Composés, compositions et méthodes pour le traitement d'une maladie | |
WO2016172496A8 (fr) | Inhibiteurs de lsd1 et leurs utilisations | |
WO2015101958A3 (fr) | Nouveaux inhibiteurs de glutaminase | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
WO2017210545A8 (fr) | Modulateurs des canaux potassiques | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
WO2017136450A3 (fr) | Composés et méthodes de traitement de maladies médiées par l'arn | |
WO2016125192A3 (fr) | Procédé de préparation de dolutégravir | |
WO2015104658A3 (fr) | Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
TN2019000211A1 (en) | Antitumoral compounds | |
WO2019078968A3 (fr) | Composés cycliques en tant qu'agents immunomodulateurs | |
WO2018125880A8 (fr) | Activateur de nrf2 | |
WO2016167944A3 (fr) | Compositions et méthodes permettant de traiter l'hyperperméabilité intestinale | |
EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
WO2019109067A3 (fr) | Promédicaments à base de créatine, compositions et procédés d'utilisation associés | |
WO2017095950A3 (fr) | Composés pour traiter des maladies prolifératives | |
WO2016135456A3 (fr) | Aortopathie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18883842 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3082184 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020527818 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018375199 Country of ref document: AU Date of ref document: 20181203 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018883842 Country of ref document: EP Effective date: 20200701 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18883842 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020010805 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020010805 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200528 |